We aimed to elucidate characteristics of beriberi neuropathy (BB) in a general hospital (GH) setting. Nerve conduction studies (NCS), cross-referenced with clinical records of patients admitted to a GH (May 2011-July 2017), were reviewed for diagnosis of BB. Thirteen patients (age range 23-64 years; five women) were diagnosed with BB. Eleven were incarcerated (2-24 months) at time of index event. Eleven reported prior, severe anorexia (2-6 months); five reported significant weight loss, three had recurrent vomiting, and three reported alcohol misuse. Commonest presentation was weakness (12/13); nine had symptom evolution over ≥3 weeks. At nadir, 11/13 could not walk independently. Other features included numbness/paraesthesiae (10/13), dysautonomia (6/13), vocal cord dysfunction/dysphagia (4/13), nystagmus (3/13). Pain was not prominent. Cerebrospinal fluid, tested in five patients, was acellular; one showed mildly increased protein. NCS showed predominantly sensorimotor, axonal polyneuropathy, rarely asymmetric. Only one patient had sural-sparing pattern. All received high dose thiamine. Two of the thirteen received intravenous immunoglobulin for suspicion of Guillain-Barré syndrome (GBS). Eleven improved to independent ambulation. One patient died from pulmonary embolism; one was lost to follow-up. Two of the thirteen had residual neurocognitive effects; both misused alcohol. Besides GBS, BB is an important cause of acute to subacute flaccid paralysis, especially in incarcerated patients and those with significant dietary deprivation. Features favoring BB over GBS are ≥3 weeks of symptoms, nystagmus, confusion, vocal cord dysfunction, volume overload, normal spinal fluid, elevated lactate, and absence of sural-sparing pattern in NCS.
Patients with a pre-existent polyneuropathy and those with incomplete clinical data were excluded from this study. Demographic, clinical, laboratory, and electrophysiological data were collated. The study was approved by the hospital's institutional review board (CIRB 2017/2558).
| RESULTS
Thirteen patients with BB were identified over a period of 74 months (Figure 1 ). Baseline demographic and clinical characteristics are summarized in Table 1 . Nine were male, and age ranged from 23 to 64 years. Eleven patients were incarcerated prior to onset of index symptoms, duration ranging from 2 to 24 months. Three patients had a history of alcohol misuse; one still drinking. Two patients had history of psychiatric illness. Eleven patients reported a significant, voluntary reduction in oral intake over the preceding 2 to 6 months. Of the remaining two, one patient had poor oral intake (2-3 weeks) during hospitalization for sepsis. In the other patient, with history of chronic alcoholism, reduced dietary intake was suspected but unconfirmed.
Significant weight loss (more than 10 kg over 3 months) was documented in five patients; while three patients had recurrent vomiting.
Clinical features are summarized in Figure 2 . Weakness, predominantly in lower limbs, was the commonest presenting symptom (12/13), evolving over a few days to 4 months. Nine patients reported symptom evolution over 3 weeks or longer. Asymmetric weakness was reported in three patients. At nadir, eleven patients could not walk independently. Sensory complaints were reported either in lower limbs (6/ 10), upper and lower limbs (3/10) or in the upper limbs only (1/10). Pain was reported in only three patients. Six patients had dysautonomia (three urinary retention/incontinence; two persistent, unexplained tachycardia; one orthostatic hypotension), and two had unexplained pedal edema, likely from mild cardiac failure and/or low oral prednisolone for a few weeks, in addition to intravenous thia- 
